ASND vs. SWTX: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ASND and SWTX, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
ASND dominates in value with a market cap of 9.55 billion USD, eclipsing SWTX’s 3.48 billion USD by roughly 2.74×.
SWTX carries a higher beta at 0.77, indicating it’s more sensitive to market moves, while ASND remains steadier at 0.40.
ASND trades as an ADR, giving U.S. investors a simple on-ramp to its foreign shares, while SWTX remains a standard domestic listing.
Symbol | ASND | SWTX |
---|---|---|
Company Name | Ascendis Pharma A/S | SpringWorks Therapeutics, Inc. |
Country | DK | US |
Sector | Healthcare | Healthcare |
Industry | Biotechnology | Biotechnology |
CEO | Mr. Jan Moller Mikkelsen | Mr. Saqib Islam J.D. |
Price | 158.1 USD | 46.21 USD |
Market Cap | 9.55 billion USD | 3.48 billion USD |
Beta | 0.40 | 0.77 |
Exchange | NASDAQ | NASDAQ |
IPO Date | January 28, 2015 | September 13, 2019 |
ADR | Yes | No |
Performance Comparison
This chart compares the performance of ASND and SWTX over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ASND and SWTX based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- Neither ASND nor SWTX turned a profit—both carry negative P/E ratios of -24.55 and -13.63, underscoring continued losses that pressure their valuations.
- Analysts assign negative forward PEG ratios to both ASND (-2.23) and SWTX (-6.77), suggesting expectation of shrinking or negative earnings in the upcoming period—a worrying sign for their profit outlook.
- ASND has a negative P/B ratio of -44.19, indicating its liabilities exceed assets (negative equity). SWTX, with a P/B of 8.29, maintains positive shareholder equity.
- ASND and SWTX both consumed more free cash flow than they generated last year—P/FCF of -27.43 and -19.97, respectively—highlighting persistent liquidity pressure.
Symbol | ASND | SWTX |
---|---|---|
Price-to-Earnings Ratio (P/E, TTM) | -24.55 | -13.63 |
Forward PEG Ratio (TTM) | -2.23 | -6.77 |
Price-to-Sales Ratio (P/S, TTM) | 22.88 | 15.84 |
Price-to-Book Ratio (P/B, TTM) | -44.19 | 8.29 |
Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -27.43 | -19.97 |
EV-to-EBITDA (TTM) | -35.74 | -13.07 |
EV-to-Sales (TTM) | 23.78 | 15.59 |
EV-to-Free Cash Flow (TTM) | -28.50 | -19.64 |
Dividend Comparison
Neither ASND nor SWTX currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
Symbol | ASND | SWTX |
---|---|---|
Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ASND and SWTX, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ASND’s quick ratio of 0.71 suggests it may struggle to cover immediate liabilities without selling inventory or raising cash, whereas SWTX at 4.18 maintains a comfortable buffer of liquid assets.
- ASND has negative equity (debt-to-equity ratio -4.46), an unusual warning sign, while SWTX at 0.02 maintains a conventional debt-to-equity balance.
- With negative EBIT (-3.72), ASND cannot cover its interest payments. SWTX, with an interest coverage of 265.27, meets its interest obligations.
Symbol | ASND | SWTX |
---|---|---|
Current Ratio (TTM) | 1.04 | 4.33 |
Quick Ratio (TTM) | 0.71 | 4.18 |
Debt-to-Equity Ratio (TTM) | -4.46 | 0.02 |
Debt-to-Assets Ratio (TTM) | 0.80 | 0.01 |
Interest Coverage Ratio (TTM) | -3.72 | 265.27 |